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The purpose of this study was to prepare and characterize mupirocin-loaded polymeric nanocapsules 
using two different oils and to develop and validate an analytical method for quantitative determination by 
high performance liquid chromatography. The mean size of the nanoparticles was 233.05 nm and 275.03 
nm for nanocapsules with a rosemary oil like oily core and caprylic/capric triglyceride, respectively, and 
a good polydispersity index below 0.25 for both formulations. The nanocapsules showed good stability 
when stored at 40 ºC and room temperature for 30 days. The quantitative method was performed with a 
mobile phase consisting of ammonium ammonium acetate (0.05 M adjusted to pH 5.0 with acetic acid) 
and acetonitrile 60:40 (v/v); the flow rate was 0.8 mL/min, UV detection at 230 nm. The analytical method 
was linear in the range of 5.0-15.0 µg/mL, specific for both oils, accurate, precise (intermediate precision 
RSD = 1.68% and repeatability RSD = 0.81%) and robust under the evaluated conditions. Therefore, this 
method can be performed for quantification of mupirocin in polymeric nanocapsules containing both oils.
Uniterms: Mupirocin/High Performance Liquid Chromatography. Mupirocin/Polymeric nanocapsules. 
Rosemary oil.
INTRODUCTION
Mupirocin (MUP) is an antibiotic used to treat 
skin surface infections. It is highly effective against 
Staphylococcus and Streptococcus, and is utilized to 
control methicillin-resistant Staphylococcus aureus. 
The chemical structure consists of a chain of fatty acids 
loaded on monic acid by an ester type linkage that 
mimics the carbon skeleton of isoleucine, competing 
with this aminoacid for the active site of isoleucyl-tRNA 
bacterial synthetase, inhibiting bacterial protein synthesis. 
However, reports of increased resistance to mupirocin are 
a matter of concern (Martindale, 2011; Poovelikunnel, 
Gethin, Humphreys, 2015; Sutherland et al., 1985; 
Thomas et al., 2010).
MUP is a crystalline white powder, slightly soluble 
in water, freely soluble in acetone and dichloromethane. 
It is a strong acid with a pKa value 4.83, presenting a 
molecular formula C26H44O9, melting point about 77–78 ºC 
and a partition coefficient of 2.25 (British Pharmacopeia, 
2012; Martindale, 2011; USP, 2012).
Recently, several studies have reported utilizing 
molecules with activity against microorganisms that are 
capable of forming biofilm in different places (Comin et 
al., 2016; Iannitelli et al., 2011; Jain et al., 2009; Maryam 
et al., 2015). Along these lines, MUP-loaded polymeric 
nanocapsules were developed by our research group 
in an attempt to increase the activity of MUP against 
Staphylococcus aureus.
Nanocapsules are vesicular systems in which 
the drug is confined to a cavity surrounded by a single 
polymer. These systems present a particle size less than 
1 µm. They have the capacity to control the drug release 
profile, increase the stability of drugs during storage and 
provide vectoring through organs and cells (Couvreur et 
al., 2002; Schaffazick et al., 2003, Zili, Sfar, Fessi, 2005). 
In order to ensure reliable and interpretable 
information about a sample, the analytical methods must 
first be validated. The validation of the analytical method 
is a continuous process that starts by planning an analytical 
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and continuous strategy throughout the development 
period (Ribani et al., 2004).
Some analytical methods have been described in the 
literature for the determination of MUP in pharmaceutical 
formulations, liposomal hydrogels, and penetrations 
studies (Berg, 2011; Echevarría et al., 2003; Jagota et al., 
1992; Shailesh, Kulkarni, 2014). Official techniques for 
quality control of MUP in raw material, cream, ointment 
and, nasal ointment are described in the United States 
Pharmacopeia (USP, 2012) and British Pharmacopeia 
(2012).
Due to the lack of a methodology for the determination 
of MUP in polymeric nanocapsules, this study aimed to 
develop and validate a method for the determination of 
MUP in polymeric nanocapsules containing essential oil 
of rosemary and caprylic/capric triglyceride, as well as to 
study the stability and the physical-chemical properties of 
the different formulations).
MATERIAL AND METHODS
Reagents and materials
MUP with 100.0% purity standard substance was 
obtained from The United States Pharmacopeia, batch 
G0M003. The MUP raw material batch: 15537/2014 
(purity 96.9%) was kindly supplied by Cristália®. 
The polymeric nanocapsule excipients were: poly(ε-
caprolactone) (PCL, MW: 70000-90000) and sorbitan 
monostearate 60 (Span®60) which were purchased 
from Sigma-Aldrich® (São Paulo, Brazil), essential 
oil of rosemary was purchased from Petite Marie® 
(Itaquaquecetuba, Brazil), caprylic/capric triglyceride 
(Crodamol® GTCC) from Alpha Química® (Porto Alegre, 
Brazil), polysorbate 80 (Tween® 80) purchase from Synth® 
and acetone from Synth®. All other reagents and solvents 
used were of analytical grade. 
Instrumentation and chromatography conditions
The apparatus used for the LC analysis was a 
Shimadzu® system (Kyoto, Japan), equipped with an LC-
20AT pump, SIL-20A ht auto sampler, CTO-20AC column 
oven, SPD-M20A PDA detector, CBM-20A system 
controller, and LC solution software was used to quantify 
the samples. The Ultra Basic Denver potentiometer was 
used to determine the pH of all solutions. Chromatography 
separations were achieved using the modified method of 
the British Pharmacopeia (2012). The separations were 
performed with a Merck® C18 column (250 mm x 4.6 
mm, 5 μm) at 25 °C. The mobile phase composition was 
ammonium acetate (0.05 M adjusted to pH 5.0 with acetic 
acid) and acetonitrile 60:40 (v/v). The flow rate was 0.8 
mL/min, the UV detection was set at 230 nm and the 
injected volume was 10 µL.
Development and characterization of polymeric 
nanocapsules containing mupirocin
Before polymeric nanocapsules were developed, 
drug solubility had to be studied in two different oils. 
Briefly, an excess amount of MUP was transferred to 
an individual erlenmeyer containing 2 mL of each oil. 
The flasks were covered and shaken at 120 rpm in an 
orbital incubator (Novatecnica®, NT712) for 24 hours at 
37 ± 0.5 ºC. After equilibrium, samples were centrifuged 
at 4000 rpm for 10 minutes, and then the concentration 
of MUP in oil was determined by the HPLC method 
described above.
Polymeric nanocapsules containing MUP were 
prepared by nanoprecipitation of pre-formed polymers 
(Fessi et al., 1989). The organic phase was constituted 
by PCL (100.0 mg), sorbitan monostearate 60 (76.6 
mg), essential oil of rosemary (330.0 mg) and mupirocin 
(10.0 mg) dissolved in acetone (27.0 mL). This organic 
phase was added with moderate magnetic stirring into an 
aqueous phase constituted by the polysorbate 80 (76.6 
mg) dissolved in water (55.0 mL). The aqueous phase 
quickly turned milky with bluish opalescence due to the 
formation of the nanoparticles. After nanoprecipitation, 
the acetone and a part of water were removed in a rotary 
evaporator and the nanoparticles were concentrated 
to a final volume of 10 mL (1.0 mg/mL of MUP). 
This formulation was called polymeric nanocapsules 
of mupirocin and rosemary (NCMR). The polymeric 
nanocapsules containing caprylic/capric triglyceride 
were prepared using the same procedure, but the core 
oil was formed by caprylic/capric triglyceride (330.0 
mg). Thus, the given name of this formulation was 
polymeric nanocapsules of mupirocin and caprylic/capric 
triglyceride (NCMT). 
The unloaded nanocapsules of rosemary oil and 
caprylic/capric triglyceride were called BNCR and BNCT, 
respectively. These formulations were prepared by the 
same method but without adding the drug.
Characterization of polymeric nanocapsules
Particle-size, zeta potential and pH: the zeta 
potential and particle-size distribution of the formulations 
were determined by Zetasizer Nano ZS® (Nanoseries, 
Malvern, UK). In both determinations, samples were 
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diluted in Milli-Q water. The pH values were determined 
by an Ultra Basic Denver® potentiometer calibrated with 
pH 4.0 and 7.0 solutions. The nanoparticles were analyzed 
directly on the electrode. The reported results are the mean 
values obtained after analyzing three batches of each 
formulation.
Determination of drug content and encapsulation 
efficiency
For the analysis of drug from nanocapsules, a 
quantity equivalent to 1000 µg of drug was transferred 
to a 10 mL volumetric flask and dispersed in acetonitrile. 
To optimize the extraction method the volumetric flasks 
were kept under sonication for 15 min. Then a 1.0 mL 
aliquot was pipetted into a 10 mL volumetric flask and 
diluted with the same solvent. The samples were then 
filtered using a nylon membrane with 0.45 µm porosity. 
The analysis was performed using the previously 
developed HPLC method.
To determine the encapsulation efficiency 300 
µL of each formulation were placed in Amicon Ultra® 
filters and centrifuged at 10000 rpm for 15 minutes. The 
encapsulation efficiency was calculated by the difference 
between the total drug content and the drug content found 
in the ultrafiltrate. 
Stability evaluation
The different nanoparticles were kept at room 
temperature and at 40 ºC for 30 days. The effects of storage 
time (0, 15 and 30 days) on the pH, particle size, zeta 
potential, drug content and encapsulation efficiency were 
determined. The stability studies were performed in three 
different batches of each formulation.
Development and validation of the HPLC method
The method was validated according to the official 
guidelines (ANVISA, 2003; ICH, 2005; INMETRO, 
2007). The parameters evaluated were: specificity, 
linearity, precision, accuracy, robustness, detection 
and quantification limits. The polymeric nanocapsules 
(NCMR) were used to develop this method.
Specificity
Method specificity was assessed using a standard 
solution containing MUP, samples of MUP-loaded 
polymeric nanocapsules (NCMR and NCMT) and 
nanoparticles without MUP (BNCR and BNCT). 
Moreover, the specificity was evaluated for stress testing 
(ICH, 2005). All the samples were analyzed in triplicate. 
The stress conditions follow:
Hydrolytic conditions: 10 mg of MUP reference 
substance were dissolved in a 10 mL volumetric flask 
with acetonitrile. Then, a 1 mL aliquot was transferred to 
a 10 mL volumetric flask and dissolved in HCl 0.1 M and 
NaOH 0.1 M. After 24 hours, the samples were neutralized 
and analyzed.
Photolytic degradation: 10 mg of MUP reference 
substance were dissolved in a 10 mL volumetric flask 
with acetonitrile. Next, a 1 mL aliquot was transferred to 
a 10 mL volumetric flask and dissolved with acetonitrile. 
This solution was exposed to UV light (ʎ = 254 nm) for 
24 hours. Then, a 1 mL aliquot was transferred to a 10 mL 
volumetric flask and dissolved with acetonitrile. 
Oxidative condition: 10.0 mg of MUP reference 
substance were dissolved in a 10 mL volumetric 
flask with acetonitrile. After that, a 1 mL aliquot was 
transferred to a 10 mL volumetric flask and dissolved in 
hydrogen peroxide 3%. After, 24 hours, a 1 mL aliquot 
was transferred to a 10 mL volumetric flask and dissolved 
in acetonitrile.
Temperature condition: 10 mg of MUP reference 
substance were dissolved in a 10 mL volumetric flask 
with acetonitrile. Then, a 1 mL aliquot was transferred to 
a 10 mL volumetric flask and dissolved with acetonitrile. 
This solution was exposed at 40 ºC. After 24 hours, a 
1 mL aliquot was transferred to a 10 mL volumetric flask 
and dissolved in acetonitrile.
Linearity and detection and quantification limits
Linearity was determined by constructing three 
independent analytical curves (n=3) with five linear 
concentrations of MUP (5.0, 8.0, 10.0, 12.0 and 
15.0 µg/mL). All concentrations were diluted in acetonitrile 
and analyzed in triplicate on three consecutive days. The 
results were assessed by regression analysis using the 
least squares method to calculate the calibration curves. 
The detection and quantification limits were determined 
using an average standard curve, considering the intercept 
standard deviation and slope.
Precision
Precision was investigated with respect to 
repeatability (intra-day) and intermediate precision 
(inter-day). Repeatability was assessed by assaying the 
concentrations of 5.0, 10.0 and 15.0 μg/mL, in triplicate 
during the same day, by the same analyst and using 
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the same instrumentation. Intermediate precision was 
assessed by carrying out the same analysis on 3 different 
days, with different instrumentation and analyst. This 
parameter was expressed as % of relative standard 
deviation (RSD).
Accuracy (Recovery method)
Accuracy was evaluated at concentration levels 
of 80, 100 and 120% where a known amount of MUP 
standard solution was added to sample solution. The 
theoretical and the measured concentration were then 
compared. The experiments were repeated three times.
Robustness
Robustness was evaluated using the method 
proposed by Youden, Steiner (1975). Small variations 
were induced in the nominal values of the method. The 
four parameters and the variations variations introduced 
are shown in Table I. Then, eight runs were performed 
to determine the influence of each parameter on the final 
results. According to Nogueira et al. (2011), this method 
will be robust if conditions 1 and 2 are met: 
Condition 1: (for factor A and other factors) content 
of MUP – 5% ≤ A ≤ content of MUP + 5%.
Condition 2: (for factor A and other factors) A – a ≤ 
3% involving the MUP content.
An aliquot of each sample was transferred into an 
individual 10 mL volumetric flask, diluted to volume with 
acetonitrile, and filtered through a nylon membrane with 
0.45 µm porosity, obtaining the final MUP concentration 
of 10.0 μg/mL. The concentrations of MUP presented in 
samples were determined from the analytical curve.
System suitability
System suitability was evaluated by five replicate 
analyses of MUP reference substance at a concentration 
of 10 μg/mL. The parameters assessed were: number of 
theoretical plates and tailing factor.
Statistical analysis
All tests were performed in 3 replicates and the 
results were expressed as average ± standard deviation. 
The results were submitted to (ANOVA) followed by 
Tukey test at a significance level of 5%. 
RESULTS AND DISCUSSION
Development and optimization of the method
The development of safe, reliable analytical 
methods is a very important tool for the quality control 
of pharmaceutical products and raw material. The 
chromatography technique is a good alternative for 
performing analysis of drug from nano-based formulations, 
since it is necessary to have a total separation of the drug 
from the formulation components (Harter et al., 2014).
Based on the official method (British Pharmacopoeia, 
2012), some chromatography conditions were evaluated to 
optimize this method. Firstly, a mobile phase was tested 
containing a mixture of methanol and water (75:25 v/v), 
however, it was not stable at baseline. Another mixture 
tested was methanol and water pH 5.0 (60:40 v/v), but 
this condition affected the retention time and shape of 
the MUP peak. Similar results were shown by Amrutiya, 
Madan, Bajaj (2010) when researching the simultaneous 
quantification of prednicarbate, MUP and ketoconazole in 
topical dosage form. In this work several eluent mixtures 
and pH values were evaluated to obtain a good separation.
System suitability
To obtain the best chromatographic method, the 
mobile phase was composed by ammonium acetate (0.05 M, 
adjusted to pH 5.0 with acetic acid) and acetonitrile 60:40 
(v/v), with a flow rate of 0.8 mL/min. These conditions 
were utilized to provide an adequate peak and satisfactory 
results according to criteria evaluated. Five replicates of 
MUP reference substance were evaluated at a concentration 
of 10 μg/mL. After chromatogram analysis, the number of 
TABLE I - Parameters and variations to evaluate the robustness of the chromatography method
Parameter Variations
Mobile phase rate (mL/min) A - 1.0 a - 0.6
Acetonitrile concentration in mobile phase (%) B - 42 b – 38
Sonication time for extraction 
of drug (minutes) C - 20 c - 10
Column supplier D - Phenomenex d – Sunfire
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theoretical plates and tailing factor were determined. The 
average values obtained were 4628 and 1.19, respectively.
Specificity
The chromatograms (Figure 1) obtained during 
the specificity test showed that none of the formulation 
excipients were eluted in the same retention time as the 
MUP peak.
Furthermore,  the interference of potential 
degradation products was investigated through a forced 
degradation test. These studies were performed to identify 
the factors that would affect the drug stability. Usually the 
range of degradation is 10% to 30% (Chan et al., 2004).
After evaluation of stress conditions (temperature 
40 ºC and oxidative 3%), the concentration remained 
constant and no possible degradation product of the 
MUP reference substance was found. In acid and basic 
hydrolysis, as well as under photolytic conditions (Figure 
2) the residual drug content after 24 hours was 10.23%, 
6.76% and 16.93%, respectively in relation to the value 
obtained in the initial analysis. 
In the chromatograms obtained after acid and basic 
hydrolysis, the formation of possible degradation products 
can be seen at about 3 min and 7 min, respectively.
Linearity
According to Figure 3, the linearity was observed 
over the concentration range of 5.0 to 15.0 µg/mL, and 
the analytical curve equation obtained was y = 18386x – 
9906 (where, x is concentration and y is the peak absolute 
area). The statistical analysis showed significant linear 
regression (Fcal = 6171.664>Ftab = 4.96) and no significant 
deviation from linearity (Fcal = 2.0031< Ftab = 3.71).
The quantification and detection limits were 
1.68 μg/mL and 0.56 μg/mL, respectively demonstrating 
the sensibility of the method for low concentrations.
Precision
This parameter was evaluated as intermediate 
precision and repeatability and was expressed as relative 
standard deviation (RSD %). Accordingly, Tables II and 
III show the mean RSD values of 1.68% and 0.69%, 
respectively, indicating the method precision over the 
concentration range. The limit recommended for this 
evaluation is RSD less than 5% (ANVISA, 2003).
Accuracy (Recovery method)
Three concentration levels and three replicates of 
each concentration were used to determine accuracy. 
The average percentage obtained was 98.85%–101.39% 
satisfying the acceptance criteria between 98.0% and 
102.0% for this study (Shabir, 2003).
Robustness
The method described by Youden, Steiner (1975), 
makes it possible not only to evaluate method robustness, 
but also to sort the variation of each parameter in the final 
results. According to Tables IV and V, the values showed 
satisfactory robustness of the method. 
FIGURE 1 - Chromatograms corresponding to: (A) solution of MUP reference substance, (B) Nanocapsules of MUP and caprylic/
capric triglyceride oil, (C) Nanocapsules of MUP and rosemary oil, (D) Unloaded nanocapsules of rosemary oil and (E) unloaded 
nanocapsules of caprylic/capric triglyceride oil.
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The variation of some method parameters did not 
change the MUP content in the sample significantly. 
The results meet conditions 1 and 2, and were therefore 
considered a robust method for the determination of MUP-
loaded polymeric nanocapsules.
Preparation and characterization of polymeric 
nanocapsules
Blank formulations and MUP-loaded polymeric 
nanocapsules were prepared through a nanoprecipitation 
technique. Table VI summarizes some physical-chemical 
characteristics after preparation of formulations containing 
the different oils. 
FIGURE 2 - Chromatograms corresponding to: (A) solution of MUP time 24 hours after acid hydrolysis, (B) solution of MUP time 
24 hours after basic hydrolysis and (C) solution of MUP time 24 hours after photolytic conditions. 
FIGURE 3 - Analytical curve of MUP.
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TABLE II - Values obtained for the intermediate precision determination for MUP-loaded polymeric nanocapsules with rosemary oil
Day N Analyst 1 Analyst 2 Average ± SD RSD (%)
1
1 98.89 96.16
98.69 ± 1.371 1.392 99.98 99.68
3 99.10 98.33
2
1 99.13 97.71
99.92 ± 1.858 1.862 103.20 100.06
3 100.38 99.04
3
1 100.59 101.24
100.59 ± 1.791 1.782 100.80 102.48
3 97.19 101.22
Average content (%) 99.73
Average RSD (%) 1.68
RSD – relative standard deviation. SD – standard deviation. 
TABLE III - Values obtained for the repeatability determination for MUP-loaded polymeric nanocapsules with rosemary oil
Sample concentration µg/mL Drug content (%) Average ± SD RSD (%)
98.38
5 98.42 98.49 ± 0.1629 0.17
98.68
97.98
10 98.80 97.92 ± 0.9063 0.93
96.99
98.56
15 100.04 98.94 ± 0.9640 0.97
98.23
Average content (%) 98.45 ± 0.5112
Average RSD (%) 0.69
RSD – relative standard deviation. SD – standard deviation.
TABLE IV - Combinations tested to evaluate the robustness, evaluating condition 1
Combination assay
Results s t u v w x y z
Contenta (%) 98.73 99.04 99.61 100.02 99.51 98.52 99.19 99.05
Average content (%) 99.21
RSD (%) 0.49
Acceptable range for content of mupirocin (%) 94.74% ≤ 99.73b ≤ 104.72%
aaverage of three determinations. bvalue obtained of intermediate precision. RSD - relative standard deviation.
Before preparing the nanocapsules, the drug solubility 
was determined between different oils. The solubilities of 
MUP in rosemary oil and caprylic/capric triglyceride 
were 263.8 mg/mL and 54.3 mg/mL respectively. All the 
formulations presented particle sizes lower than 300 nm 
with a good monomodal distribution profile. The particle 
sizes were 233.05 ± 1.94 nm and 280.13 ± 2.91 nm for 
the nanocapsules with rosemary oil and caprylic/capric 
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triglyceride oil, respectively. The polydispersity index 
(PDI) found was 0.25 and 0.22 indicating a uniform 
system size for both formulations. Similar results have 
been reported for essential oil of rosemary when prepared 
by the nanoprecipitation method (Ephrem et al., 2014). 
A PDI value lower than 0.5 is appropriate for colloidal 
suspension, indicating that the distribution size of the 
nanocapsules is homogeneous (Kumar et al., 2015; Wu, 
Zhang, Watanabe, 2011).
The pH values for NCMR and NCMT were 4.5 and 
4.4, however for BNCR and BNCT the pH values were 
5.6 and 5.8. These values can be justified by the acidic 
nature of the drug and due to the utilization of PCL around 
the core oil. In general, the pH values of the polymeric 
nanocapsules can vary from 3.0 to 7.5 when prepared 
according to the nanoprecipitation method (Mora-Huertas, 
Fessi, Elaissari, 2010).
Mupirocin was quantified after 15 min of extraction 
using acetonitrile as solvent. The average drug content in 
different formulations was 100.05 ± 0.15% (NCMR) and 
99.2 ± 0.10 % (NCMT).
Stability evaluation
In order to evaluate the stability of MUP-loaded 
polymeric nanocapsules, the formulations containing 
the drug and unloaded nanocapsules were stored at room 
temperature and at 40 ºC for 30 days. The stability was 
evaluated by comparing the initial particle size, zeta 
potential, pH, encapsulation efficiency and drug content 
with those obtained after 30 days (Table VII). 
After 30 days of storage at room temperature and 
40 ºC, considering the average particle size, all formulation 
exhibited a similar characteristic when compared to the 
formulation at the initial time (p > 0.05). After 30 days 
of storage at 40 ºC, the pH values were significantly 
reduced in all formulations compared to the formulation 
at the initial time (p<0.05). This can be explained by the 
higher temperature, promoting increased polyester rates 
of hydrolysis and a reduction of the pH values and acidic 
characteristic of the drug (Mallin et al., 1996).
The MUP-loaded polymeric nanocapsules and 
unloaded nanocapsules exhibited a similar zeta potential 
TABLE V - Combinations tested to evaluate the robustness, evaluating condition 2
Content of mupirocin (%) Difference (%) Limits for the difference  (3%*99.73a%) 
A = 99.35 a = 99.07 A – a = 0.28 2.99
Robust
B = 98.95 b = 99.47 B – b = - 0.52 2.99
C = 99.26 c = 99.16 C – c = 0.10 2.99
D = 99.00 d = 99.42 D – d = - 0.42 2.99
E = 98.98 e = 99.44 E – e = - 0.46 2.99
Average content (%): 99.21
SD: 0.2031
RSD (%): 0.2
a value of intermediate precision obtained. SD – standard deviation. RSD - relative standard deviation.
TABLE VI - Physical-chemical characteristics of nanocapsules of MUP and rosemary oil (NCMR), nanocapsules of MUP and 
caprylic/capric triglyceride oil (NCMT), unloaded nanocapsules of rosemary (BNCR) and unloaded nanocapsules of caprylic/
capric triglyceride (BNCT)
Samples Mean size
b 
± S.D. (nm) ζ-Potential
b (mV) pHb
Encapsulation 
Efficiencyb  
(% w/w)
Drug contentb 
± S.D. (%)
NCMR 233.05 ± 1.94 (0.25)a -33.44 4.5 ± 0.78 97.46 100.50 ± 0.15
BNCR 213.00 ± 2.66 (0.22)a - 33.97 5.6 ± 1.08 ------ ------
NCMT 275.03 ± 2.91 (0.22)a -32.21 4.4 ± 0.84 84.61 99.20 ± 0.10
BNCT 229.77 ± 1.72 (0.19)a - 31.10 5.8 ± 0.19 ------ ------
a polydispersity index. b values represent the average between the 3 batches.
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under both conditions (room temperature and 40 ºC). 
All values were negative, which confirms the stability of 
nanocapsules. A zeta potential value around ±30 mV is 
assumed to be good for formulations (Kumar et al., 2015). 
The negative potential values of the samples are related 
to the presence of polysorbate 80, presenting a negative 
surface density of charge (Marchiori et al., 2010). 
CONCLUSIONS
The rosemary and caprylic/capric triglyceride 
oils were used as oily core for the formulations. The 
nanoparticles showed adequate particle size, monomodal 
size distributions and low polydispersity index. All 
samples showed a reduction of pH value after storage at 40 
ºC. On the other hand, the formulations showed adequate 
zeta potential according to the literature and appropriate 
quantity of mupirocin. The proposed analytical method 
was linear, selective for both oils, precise, accurate and 
robust for the determination of MUP-loaded polymeric 
nanocapsules, showing that it is a useful method for quality 
control of the proposed delivery system. The results of the 
present study showed promising data for the development 
of a new formulation containing MUP and rosemary oil 
in an attempt to increase the activity of MUP against 
Staphylococcus aureus.
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Samples Mean size 
b 
± SD (nm) ζ-Potential
 b (mV) pHb
Encapsulation 
efficiency b 
(% w/w)
Drug content b 
± SD (%)
15 days 25 ºC 40 ºC 25 ºC 40 ºC 25 ºC 40 ºC 25 ºC 40 ºC 25 ºC 40 ºC
NCMR 238.56  
± 0.21
238.05 
± 1.08
-33.7  
± 1.85
-24.1  
± 1.02
4.4  
± 0.12 
4.1  
± 0.11
97.10 95.53 99.51  
± 0.24
97.92  
± 0.14
BNCR 221.02 
± 0.14
210.89 
± 1.58
-30.2 
± 1.08
-20.7 
± 1.77
5.4  
± 0.06
4.4  
± 0.14
------ ------ ------ ------
NCMT 268.8 
± 0.84
279.93 
± 1.26
-30.4  
± 0.88
-28.2  
± 1.08
4.5 
 ± 0.14
3.8  
± 0.09
83.19 82.48 98.90 
± 0.21
97.50  
± 0.37
BNCT 224.53 
± 0.15
234.21 
± 0.19
-32.8  
± 1.21
-28.5 
± 1.78
5.7 
± 0.17
4.5  
± 0.11
------ ------ ------ ------
30 days
NCMR 235.42 
± 0.64
241.03 
± 1.29
-31.53  
± 0.78
-25.20  
± 1.02
4.48  
± 0.07
3.67  
± 0.18
98.83 96.02 98.18 
± 1.87
98.44 
± 0.82
BNCR 218.89 
± 0.71
238.18 
± 1.04
-29.57  
± 1.94
-22.58  
± 0.88
5.42  
± 0.07
4.01 
± 0.05
------ ------ ------ ------
NCMT 273.57 
± 1.57
281.03 
± 1.35
-31.95  
± 1.33
-27.48  
± 0.91
4.38  
± 0.08
3.46  
± 0.11
84.11 85.43 99.29 
± 1.66
97.05 
± 1.3
BNCT 232.85 
± 0.85
236.85 
± 0.38
-30.01  
± 0.11
-29.73  
± 1.78
5.67  
± 0.04
4.31  
± 0.09
------ ------ ------ ------
All samples showed a polydispersity index lower than 0.25. b Values represent the average between the 3 batches. Nanocapsules 
of mupirocin and rosemary oil (NCMR). Nanocapsules of mupirocin and caprylic/capric triglyceride oil (NCMT). Unloaded 
nanocapsules of rosemary oil (BNCR). Unloaded nanocapsules of caprylic/capric triglyceride oil (BNCT).
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